Genomic-adjusted radiation dose to personalise radiotherapy

Affiliations

¹ Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; GROW-School for Oncology and Developmental Biology and MAASTRO Laboratory, Maastricht University, Maastricht 5262000, Netherlands. Electronic address: orit.kaidarPerson@sheba.health.gov.il.
² Iridium Netwerk and University of Antwerp, Wilrijk Antwerp, Belgium.
³ Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Comment

Orit Kaidar-Person et al. Lancet Oncol. 2021 Sep.

. 2021 Sep;22(9):1200-1201.

doi: 10.1016/S1470-2045(21)00411-3. Epub 2021 Aug 4.

¹ Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; GROW-School for Oncology and Developmental Biology and MAASTRO Laboratory, Maastricht University, Maastricht 5262000, Netherlands. Electronic address: orit.kaidarPerson@sheba.health.gov.il.
² Iridium Netwerk and University of Antwerp, Wilrijk Antwerp, Belgium.
³ Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

No abstract available

Conflict of interest statement

We declare no competing interests. RS is supported by a grant from the Breast Cancer Research Foundation (grant number 17-194).

Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis.
Scott JG, Sedor G, Ellsworth P, Scarborough JA, Ahmed KA, Oliver DE, Eschrich SA, Kattan MW, Torres-Roca JF. Scott JG, et al. Lancet Oncol. 2021 Sep;22(9):1221-1229. doi: 10.1016/S1470-2045(21)00347-8. Epub 2021 Aug 4. Lancet Oncol. 2021. PMID: 34363761